Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Respirerx Pharmaceuticals Inc
(OP:
RSPI
)
0.0003
UNCHANGED
Streaming Delayed Price
Updated: 1:54 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
600
Open
0.0003
Bid (Size)
N/A (0)
Ask (Size)
N/A (0)
Prev. Close
0.0003
Today's Range
0.0003 - 0.0003
52wk Range
0.0002 - 0.0069
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Stocks Under 1¢: June 2024 Gains, July 2024 Watchlist SMCE, SPZI, RSPI, HALB, BIEI, RJDG
July 03, 2024
Via
AB Newswire
RespireRx Transferes Its Pharmaceutical Cannabinoid Program To ResolutionRx
August 09, 2023
RespireRx Pharmaceuticals Inc. (OTCPK:RSPI), focused on the discovery and development of treatments to combat diseases caused by disruption of neuronal signaling, and ResolutionRx Ltd, an unlisted...
Via
Benzinga
Performance
YTD
-66.67%
-66.67%
1 Month
-70.00%
-70.00%
3 Month
-66.67%
-66.67%
6 Month
-76.92%
-76.92%
1 Year
-75.00%
-75.00%
More News
Read More
RespireRx Pharmaceuticals Inc. Enters a Collaboration With National Institute for Neurological Disorders and Stroke to Advance its Lead GABAkine Toward Clinical Development
December 05, 2022
From
RespireRX Pharmaceuticals Inc.
Via
GlobeNewswire
RespireRx Signs LOI With Australian CRO For Dronabinol Development For Obstructive Sleep Apnea
November 17, 2022
Via
Benzinga
RespireRx Pharmaceuticals Inc. Announces Entry into Letter of Intent with Australian Headquartered CRO for Dronabinol Development for Obstructive Sleep Apnea
November 17, 2022
From
RespireRX Pharmaceuticals Inc.
Via
GlobeNewswire
RespireRx Pharmaceuticals Inc. Announces that Jeff Margolis, the Company’s CFO is presenting at the Investor Summit Q4
November 10, 2022
From
RespireRX Pharmaceuticals Inc.
Via
GlobeNewswire
RespireRx Pharmaceuticals Inc. Announces that Dr. Arnold Lippa Is an Invited Speaker at the 5th Meridian Drug Discovery Summit
November 07, 2022
From
RespireRX Pharmaceuticals Inc.
Via
GlobeNewswire
RespireRx Pharmaceuticals Files Patent: Claims To Improve Solubility & Bioavailability Of Cannabinoids
March 24, 2022
Via
Benzinga
Epigenetics, Psychedelics and Stem Cell Therapy are Topics of the Life Sciences Virtual Investor Conference Launching This Thursday
December 14, 2021
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.